Cargando…

Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes

AIMS/INTRODUCTION: We investigated the difference in efficacy and safety between discontinuation and maintaining of sulfonylurea when adding a sodium–glucose cotransporter 2 inhibitor. MATERIALS AND METHODS: In the present multicenter, prospective observational study, 200 patients with type 2 diabet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takahashi, Kiyohiko, Cho, Kyu Yong, Nakamura, Akinobu, Miya, Aika, Miyoshi, Arina, Yamamoto, Chiho, Nomoto, Hiroshi, Niwa, Hirokatsu, Takahashi, Kiyohito, Manda, Naoki, Kurihara, Yoshio, Aoki, Shin, Ito, Yoichi M, Atsumi, Tatsuya, Miyoshi, Hideaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400155/ https://www.ncbi.nlm.nih.gov/pubmed/30136403 http://dx.doi.org/10.1111/jdi.12913

Ejemplares similares

Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: A randomized controlled trial
por: Takase, Takahiro, et al.
Publicado: (2018)

Reduction in glucose fluctuations in elderly patients with type 2 diabetes using repaglinide: A randomized controlled trial of repaglinide vs sulfonylurea
por: Omori, Kazuno, et al.
Publicado: (2018)

The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3)
por: Kitao, Naoyuki, et al.
Publicado: (2017)

The Association of Cardio-Ankle Vascular Index and Ankle-Brachial Index with Macroangiopathy in Patients with Type 2 Diabetes Mellitus
por: Niwa, Hirokatsu, et al.
Publicado: (2019)

Effect of switching from pioglitazone to the sodium glucose co‐transporter‐2 inhibitor dapagliflozin on body weight and metabolism‐related factors in patients with type 2 diabetes mellitus: An open‐label, prospective, randomized, parallel‐group comparison trial
por: Cho, Kyu Yong, et al.
Publicado: (2018)

Beneficial effects of switching to denosumab from bisphosphonates or selective estrogen receptor modulators in postmenopausal women with type 2 diabetes and osteopenia/osteoporosis
por: Miyoshi, Arina, et al.
Publicado: (2020)

ODP190 Efficacy of Esaxerenone on Hypertensive Patients with Type 2 Diabetes or Those with Impaired Glucose Tolerance
por: Kuwabara, Saki, et al.
Publicado: (2022)

Add-on imeglimin versus metformin dose escalation regarding glycemic control in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: study protocol for a multicenter, prospective, randomized, open-label, parallel-group comparison study (MEGMI study)
por: Nomoto, Hiroshi, et al.
Publicado: (2022)

Sodium–glucose cotransporter 2 inhibitors reduce day‐to‐day glucose variability in patients with type 1 diabetes
por: Chiba, Koki, et al.
Publicado: (2020)

Dipeptidyl peptidase‐4 inhibitor might exacerbate Graves’ disease: A multicenter observational case–control study
por: Sekizaki, Tomonori, et al.
Publicado: (2021)

Favorable effect of sodium–glucose cotransporter 2 inhibitor, dapagliflozin, on non‐alcoholic fatty liver disease compared with pioglitazone
por: Cho, Kyu Yong, et al.
Publicado: (2020)

Satisfaction of switching to combination therapy with lixisenatide and basal insulin in patients with type 2 diabetes receiving multiple daily insulin injection therapy: A randomized controlled trial
por: Miya, Aika, et al.
Publicado: (2017)

A Comparison of the Effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters: A Randomized, Controlled Trial Sapporo Athero-Incretin Study 2 (SAIS2)
por: Nomoto, Hiroshi, et al.
Publicado: (2015)

Gitelman's syndrome with hyperphosphatemia, effectively responding to single oral magnesium oxide administration: A case report
por: Miya, Aika, et al.
Publicado: (2019)

MON-492 A Case of Gitelman’s Syndrome with Hyperphosphatemia That Responded Effectively to Single Oral Administration of Magnesium Oxide
por: Miya, Aika, et al.
Publicado: (2019)

Impaired insulin secretion predicting unstable glycemic variability and time below range in type 2 diabetes patients regardless of glycated hemoglobin or diabetes treatment
por: Miya, Aika, et al.
Publicado: (2020)

ODP338 Neuromedin B Receptor Antagonist Suppresses ACTH Secretion and Cell Proliferation in Human and Mouse Corticotroph Adenoma
por: Atsumi, Tatsuya, et al.
Publicado: (2022)

Switching from Insulin Degludec plus Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide Improves Glycemic Variability in Patients with Type 2 Diabetes: A Preliminary Prospective Observation Study
por: Oe, Yuki, et al.
Publicado: (2022)

Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, parallel-group comparison study (the SWITCH-SEMA 2 study)
por: Nomoto, Hiroshi, et al.
Publicado: (2022)

Switching to Once-Daily Insulin Degludec/Insulin Aspart from Basal Insulin Improves Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus: Randomized Controlled Trial
por: Cho, Kyu Yong, et al.
Publicado: (2020)

The association between hypoglycemia and glycemic variability in elderly patients with type 2 diabetes: a prospective observational study
por: Handa, Takahisa, et al.
Publicado: (2021)

ODP332 Maternal Central Diabetes Insipidus Immediately after Delivery, Owing to Vasospasm of the Internal Carotid Artery
por: Yokozeki, Kei, et al.
Publicado: (2022)

ODP285 A Case of Encephalitis and Adrenal Insufficiency in a Patient With Panhypopituitarism After COVID-19 Vaccination
por: Yabe, Ichiro, et al.
Publicado: (2022)

ODP279 A Case of Nephrogenic Diabetes Insipidus Diagnosed at an Advanced Age in a Female Patient with an AVPR2 Gene Mutation and Skewed×Inactivation
por: Nakata, Kento, et al.
Publicado: (2022)

Log-linear relationship between endogenous insulin secretion and glycemic variability in patients with type 2 diabetes on continuous glucose monitoring
por: Miya, Aika, et al.
Publicado: (2021)

Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin
por: Miya, Aika, et al.
Publicado: (2021)

ODP328 Longitudinal Multidisciplinary Approach for Cabergoline-Resistant Aggressive Prolactinoma Complicated by Multiple Endocrine Neoplasia Type 1
por: Furusawa, Sho, et al.
Publicado: (2022)

Effect of the sodium–glucose cotransporter 2 inhibitor luseogliflozin on pancreatic beta cell mass in db/db mice of different ages
por: Takahashi, Kiyohiko, et al.
Publicado: (2018)

Effects of Switching from Liraglutide or Dulaglutide to Subcutaneous Semaglutide on Glucose Metabolism and Treatment Satisfaction in Patients with Type 2 Diabetes: Protocol for a Multicenter, Prospective, Randomized, Open-Label, Blinded-Endpoint, Parallel-Group Comparison Study (The SWITCH-SEMA 1 Study)
por: Nomoto, Hiroshi, et al.
Publicado: (2021)

Impact of Glucose Loading on Variations in CD4(+) and CD8(+) T Cells in Japanese Participants with or without Type 2 Diabetes
por: Miya, Aika, et al.
Publicado: (2018)

Correlation between serum proinsulin levels and fatty liver: The Dynamics of Lifestyle and Neighborhood Community on Health Study Health Study
por: Miya, Aika, et al.
Publicado: (2020)

A Randomized Controlled Trial Comparing the Effects of Sitagliptin and Glimepiride on Endothelial Function and Metabolic Parameters: Sapporo Athero-Incretin Study 1 (SAIS1)
por: Nomoto, Hiroshi, et al.
Publicado: (2016)

Effect of Switching to Once-Weekly Semaglutide on Non-Alcoholic Fatty Liver Disease: The SWITCH-SEMA 1 Subanalysis
por: Nomoto, Hiroshi, et al.
Publicado: (2023)

Favourable effect of the sodium‐glucose co‐transporter‐2 inhibitor canagliflozin plus the dipeptidyl peptidase‐4 inhibitor teneligliptin in combination on glycaemic fluctuation: An open‐label, prospective, randomized, parallel‐group comparison trial (the CALMER study)
por: Cho, Kyu Yong, et al.
Publicado: (2019)

Improved time in range and postprandial hyperglycemia with canagliflozin in combination with teneligliptin: Secondary analyses of the CALMER study
por: Cho, Kyu Yong, et al.
Publicado: (2021)

Potential Importance of a Histopathological Analysis in Thyroidal Diseases with High Serum IgG4 Levels
por: Nomoto, Hiroshi, et al.
Publicado: (2017)

SAT-413 Does Dipeptidyl Peptidase-4 Inhibitor Exacerbate Graves’ Disease?
por: Sekizaki, Tomonori, et al.
Publicado: (2020)

Effects of switching from a dipeptidyl peptidase-4 inhibitor to luseogliflozin on nocturnal blood pressure in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, blinded endpoint parallel-group comparison study
por: Kameda, Reina, et al.
Publicado: (2020)

Glucokinase is required for high‐starch diet‐induced β‐cell mass expansion in mice
por: Tsuchida, Kazuhisa, et al.
Publicado: (2021)

Luseogliflozin preserves the pancreatic beta-cell mass and function in db/db mice by improving mitochondrial function
por: Yamauchi, Yuki, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ip8q5355kqtr98csbd7q4qtn7v